期刊文献+

肺动脉高压发病机制研究进展 被引量:6

Study Progress of Pathogenesis of Pulmonary Arterial Hypertension
下载PDF
导出
摘要 肺动脉高压(PAH)是一种以肺血管重构为主要病理变化特征的疾病,表现为肺小血管增殖、重塑及原位血栓形成,发生过程是一个复杂的病理生理过程,其发病机制尚未完全明了。关于其发病的基因多态性研究已基本明确,同时内皮系统分泌的各种血管活性物质的研究也较深入全面,近年来离子通道等方面的研究亦为PAH的发病机制揭开一条新路。对于PAH的进一步研究应着重于其基因组、蛋白质组学及信号传导等方面,为有效治疗PAH提供思路。现就上述几个方面作一综述。
作者 王伟 王玉林
出处 《实用儿科临床杂志》 CAS CSCD 北大核心 2008年第13期1036-1038,共3页 Journal of Applied Clinical Pediatrics
  • 相关文献

参考文献19

  • 1Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2 encoding a TGF -beta recepor,cause familial primary pulmonary hypertension. The international PPH consortium [ J ]. Nat Genet,2000,26( 1 ) :81 -84.
  • 2Aldred MA, Vijayakrlshnan J, James V, et al. BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension [ J ]. Hum Murat, 2006,27 (2) :212 -213.
  • 3Song Y,Jones JE,Beppu H,et al. Increased susceptibility to pulmonary hypertension in heterozygous BMPR2 - mutant mice [ J ]. Circulal ,n, 2005,112(4) :553 -562.
  • 4Teichert - Kuliszewska K, Kutryk M J, Kuliszewski MA, et al. Bone morphogenetic protein receptor -2 signaling promotes pulmonary arterial endothelial cell survival : Implications for loss - of - function mutations in the pathogenesis of pulmonary hypertension [ J ]. Circ Res ,2006 ,98 (2) : 209 -217.
  • 5Atkinson C, Stewart S, Upton PD,et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type Ⅱ bone morphogenetic protein receptor [ J ]. Circulation, 2002,105 ( 14 ) : 1672 - 1678.
  • 6Kitaura H, Uozumi N ,Tohmi M ,et al. Roles of nitric oxide as a vasodilatot in neurovascular coupling of mouse somatosensory cortex[ J]. Neurosci Res,2007,59(2) :160 - 171.
  • 7Fisher KA, Serlin DM, Wilson KC ,et al. Sarcoidosis -associated pulmonary hypertension:Outcome with long -term epoprostenol treatment[ J ]. Chest ,2006,130(5 ) : 1481 - 1488.
  • 8Achcar RO, Yung GL, SalTer H ,et al. Morphologic changes in explanted lungs after prostacyclin therapy for pulmonary hypertension [ J ]. Eur J Med Res ,2006,11 ( 5 ) :203 - 207.
  • 9Opitz CF, Ewert R. Dual ET( A )/ET( B ) vs. selective ET( A ) endothelin receptor antagonism in patients with pulmonary hypertension [ J ]. Eur J Clin Invest ,2006,36( suppl 3 ) : 1 - 9.
  • 10Jacobs A, Preston IR, Gomberg - Maitland M. Endothelin receptor antagonism in pulmonary arterial hypertension - a role for selective ET ( A ) inhibition [ J ] ? Curt Med Res Opin ,2006,22 ( 12 ) :2567 - 2574.

同被引文献57

引证文献6

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部